Moderna Inc. (MRNA) Stock Analysis 2026

Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics. The company's mRNA COVID-19 vaccine (Spikevax) generated $36B+ in cumulative revenue and validated mRNA as a viable drug development platform. Post-pandemic, Moderna is building on this platform to develop vaccines for RSV (approved 2024), flu, cancer (personalized neoantigen vaccines with Merck), rare diseases, and autoimmune conditions. The company has the broadest mRNA pipeline in the industry with 40+ programs.

This chart shows how Moderna's revenue flows through to profit. As a financial-sector company, Moderna doesn't report a traditional cost-of-revenue/gross-margin split, so the cascade starts from operating expenses and works down to net income — the actual profit shareholders own. A high net margin indicates efficient expense control and capital allocation.

Moderna Inc. doesn't carry a meaningful trailing P/E right now, generates $299.2M in free cash flow, runs a debt/equity ratio of 19.04, and converts shareholder equity into profit at a -39.0% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Wall Street analysts covering Moderna Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $106.63 (-30.8% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

MRNA is currently in a golden cross pattern, trading above its 50-day average of $78.32 and above its 200-day average of $52.33. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

MRNA's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.